Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation

Trial Profile

Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs 64Cu-MeCOSar-Octreotate (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Clarity Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2018 Status changed to withdrawn prior to enrolment.
    • 14 Feb 2018 Planned initiation date changed from 25 Sep 2017 to 5 Mar 2018.
    • 08 Dec 2017 According to a Clarity Pharmaceuticals media release, Additional sites in Australia and the USA will be activated over the coming months in order to fast-track the completion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top